☰

Anita B. Hjelmeland, Ph.D. - Publications

Affiliations: 
2003 Duke University, Durham, NC 
Area:
Somatosensory
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

108 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Hawkins CC, Jones AB, Gordon ER, Harsh Y, Ziebro JK, Willey CD, Griguer C, Crossman DK, Cooper SJ, Ramanadham S, Doan N, Hjelmeland AB. Carmofur prevents cell cycle progression by reducing E2F8 transcription in temozolomide-resistant glioblastoma cells. Cell Death Discovery. 9: 451. PMID 38086808 DOI: 10.1038/s41420-023-01738-x  0.401
2023 Miller CR, Hjelmeland AB. Breaking the feed forward inflammatory cytokine loop in the tumor microenvironment of PDGFB-driven glioblastomas. The Journal of Clinical Investigation. 133. PMID 37966120 DOI: 10.1172/JCI175127  0.315
2023 Jones AB, Schanel TL, Rigsby MR, Griguer CE, McFarland BC, Anderson JC, Willey CD, Hjelmeland AB. Tumor Treating Fields Alter the Kinomic Landscape in Glioblastoma Revealing Therapeutic Vulnerabilities. Cells. 12. PMID 37681903 DOI: 10.3390/cells12172171  0.358
2023 Watson DC, Bayik D, Storevik S, Moreino SS, Sprowls SA, Han J, Augustsson MT, Lauko A, Sravya P, Røsland GV, Troike K, Tronstad KJ, Wang S, Sarnow K, Kay K, ... ... Hjelmeland AB, et al. GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity. Nature Cancer. PMID 37169842 DOI: 10.1038/s43018-023-00556-5  0.342
2022 Guo Y, Jiang Y, Rose JB, Nagaraju GP, Jaskula-Sztul R, Hjelmeland AB, Beck AW, Chen H, Ren B. Protein Kinase D1 Signaling in Cancer Stem Cells with Epithelial-Mesenchymal Plasticity. Cells. 11. PMID 36497140 DOI: 10.3390/cells11233885  0.441
2022 Marayati R, Julson J, Bownes LV, Quinn CH, Stafman LL, Beierle AM, Markert HR, Hutchins SC, Stewart JE, Crossman DK, Hjelmeland AB, Mroczek-Musulman E, Beierle EA. PIM3 kinase promotes tumor metastasis in hepatoblastoma by upregulating cell surface expression of chemokine receptor cxcr4. Clinical & Experimental Metastasis. 39: 899-912. PMID 36315303 DOI: 10.1007/s10585-022-10186-3  0.356
2022 Hawkins CC, Jones AB, Gordon ER, Williford SE, Harsh Y, Ziebro JK, Landis CJ, Gc S, Crossman DK, Cooper SJ, Ramanadham S, Doan N, Hjelmeland AB. Targeting Acid Ceramidase Inhibits Glioblastoma Cell Migration through Decreased AKT Signaling. Cells. 11. PMID 35741006 DOI: 10.3390/cells11121873  0.366
2022 Marayati R, Julson JR, Bownes LV, Quinn CH, Hutchins SC, Williams AP, Markert HR, Beierle AM, Stewart JE, Hjelmeland AB, Mroczek-Musulman E, Beierle EA. Metastatic human hepatoblastoma cells exhibit enhanced tumorigenicity, invasiveness and a stem cell-like phenotype. Journal of Pediatric Surgery. PMID 35300860 DOI: 10.1016/j.jpedsurg.2022.01.063  0.328
2021 Tuy K, Rickenbacker L, Hjelmeland AB. Reactive oxygen species produced by altered tumor metabolism impacts cancer stem cell maintenance. Redox Biology. 44: 101953. PMID 34052208 DOI: 10.1016/j.redox.2021.101953  0.348
2021 Williford SE, Libby CJ, Ayokanmbi A, Otamias A, Gordillo JJ, Gordon ER, Cooper SJ, Redmann M, Li Y, Griguer C, Zhang J, Napierala M, Ananthan S, Hjelmeland AB. Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells. Plos One. 16: e0250649. PMID 33945569 DOI: 10.1371/journal.pone.0250649  0.323
2021 Libby CJ, Gc S, Benavides GA, Fisher JL, Williford SE, Zhang S, Tran AN, Gordon ER, Jones AB, Tuy K, Flavahan W, Gordillo J, Long A, Cooper SJ, Lasseigne BN, ... ... Hjelmeland AB, et al. A role for GLUT3 in glioblastoma cell invasion that is not recapitulated by GLUT1. Cell Adhesion & Migration. 15: 101-115. PMID 33843470 DOI: 10.1080/19336918.2021.1903684  0.35
2021 Boyd NH, Tran AN, Bernstock JD, Etminan T, Jones AB, Gillespie GY, Friedman GK, Hjelmeland AB. Glioma stem cells and their roles within the hypoxic tumor microenvironment. Theranostics. 11: 665-683. PMID 33391498 DOI: 10.7150/thno.41692  0.433
2021 Boyd NH, Tran AN, Bernstock JD, Etminan T, Jones AB, Gillespie GY, Friedman GK, Hjelmeland AB. Glioma stem cells and their roles within the hypoxic tumor microenvironment Theranostics. 11: 665-683. DOI: 10.7150/thno.41692  0.43
2020 Eustace NJ, Anderson JC, Warram JM, Widden HN, Pedersen RT, Alrefai H, Patel Z, Hicks PH, Placzek WJ, Gillespie GY, Hjelmeland AB, Willey CD. A cell-penetrating MARCKS mimetic selectively triggers cytolytic death in glioblastoma. Oncogene. PMID 33077834 DOI: 10.1038/s41388-020-01511-9  0.313
2020 Hawkins CC, Ali T, Ramanadham S, Hjelmeland AB. Sphingolipid Metabolism in Glioblastoma and Metastatic Brain Tumors: A Review of Sphingomyelinases and Sphingosine-1-Phosphate. Biomolecules. 10. PMID 32977496 DOI: 10.3390/biom10101357  0.337
2019 Hjelmeland AB, Patel RP. SOD2 acetylation and deacetylation: Another tale of Jekyll and Hyde in cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 31694886 DOI: 10.1073/Pnas.1916214116  0.58
2019 Dorsett KA, Jones RB, Ankenbauer KE, Hjelmeland AB, Bellis SL. Sox2 promotes expression of the ST6Gal-I glycosyltransferase in ovarian cancer cells. Journal of Ovarian Research. 12: 93. PMID 31610800 DOI: 10.1186/S13048-019-0574-5  0.444
2019 Libby CJ, McConathy J, Darley-Usmar V, Hjelmeland AB. The Role of Metabolic Plasticity in Blood and Brain Stem Cell Pathophysiology. Cancer Research. PMID 31575548 DOI: 10.1158/0008-5472.Can-19-1169  0.455
2019 Wang J, Leavenworth JW, Hjelmeland AB, Smith R, Patel N, Borg B, Si Y, King PH. Deletion of the RNA regulator HuR in tumor-associated microglia and macrophages stimulates anti-tumor immunity and attenuates glioma growth. Glia. PMID 31400163 DOI: 10.1002/Glia.23696  0.471
2019 Wang J, Hjelmeland AB, Nabors LB, King PH. Anti-cancer effects of the HuR inhibitor, MS-444, in malignant glioma cells. Cancer Biology & Therapy. 1-10. PMID 30991885 DOI: 10.1080/15384047.2019.1591673  0.445
2019 Eustace NJ, Anderson JC, Langford CP, Trummell HQ, Hicks PH, Jarboe JS, Mobley JA, Hjelmeland AB, Hackney JR, Pedersen RT, Cosby K, Gillespie GY, Bonner JA, Willey CD. Myristoylated alanine-rich C-kinase substrate effector domain phosphorylation regulates the growth and radiation sensitization of glioblastoma. International Journal of Oncology. PMID 30942445 DOI: 10.3892/Ijo.2019.4766  0.322
2019 Boyd NH, Walker K, Ayokanmbi A, Gordon ER, Whetsel J, Smith CM, Sanchez RG, Lubin F, Chakraborty A, Tran AN, Herting C, Hambardzumyan D, Yancey Gillespie G, Hackney JR, Cooper SJ, ... ... Hjelmeland AB, et al. CHD7 is Suppressed in the Perinecrotic/Ischemic Microenvironment and is a Novel Regulator of Glioblastoma Angiogenesis. Stem Cells (Dayton, Ohio). PMID 30629778 DOI: 10.1002/Stem.2969  0.516
2019 Wang J, Leavenworth J, Hjelmeland A, Borg B, King PH. Abstract 147: Deletion of the RNA regulator HuR in microglia/macrophages promotes an anti-tumor microenvironment in glioblastoma Cancer Research. 79: 147-147. DOI: 10.1158/1538-7445.Am2019-147  0.475
2019 GC S, Libby C, Zhang S, Benavides G, Scott S, Li Y, Tran A, Otamias A, Darley-Usmar V, Napierala M, Pathak V, Moukha-Chafiq O, Augelli-Szafran C, Zhang W, Hjelmeland A. DDIS-24. DECREASE IN GLIOBLASTOMA GROWTH IN VITRO WITH TREATMENT OF NOVEL ANALOGS OF GLUCOSE TRANSPORTER INHIBITORS Neuro-Oncology. 21: vi68-vi68. DOI: 10.1093/Neuonc/Noz175.275  0.466
2019 Scott JG, Dhawan A, Hjelmeland A, Lathia J, Chumakova A, Hitomi M, Fletcher AG, Maini PK, Anderson ARA. Recasting the Cancer Stem Cell Hypothesis: Unification Using a Continuum Model of Microenvironmental Forces Current Stem Cell Reports. 5: 22-30. DOI: 10.1007/S40778-019-0153-0  0.477
2018 Oliva CR, Halloran B, Hjelmeland AB, Vazquez A, Bailey SM, Sarkaria JN, Griguer CE. IGFBP6 controls the expansion of chemoresistant glioblastoma through paracrine IGF2/IGF-1R signaling. Cell Communication and Signaling : Ccs. 16: 61. PMID 30231881 DOI: 10.1186/S12964-018-0273-7  0.477
2018 Garner EF, Stafman LL, Williams AP, Aye JM, Goolsby C, Atigadda VR, Moore BP, Nan L, Stewart JE, Hjelmeland AB, Friedman GK, Beierle EA. UAB30, a novel RXR agonist, decreases tumorigenesis and leptomeningeal disease in group 3 medulloblastoma patient-derived xenografts. Journal of Neuro-Oncology. PMID 30132166 DOI: 10.1007/S11060-018-2950-1  0.379
2018 Walker K, Boyd NH, Anderson JC, Willey CD, Hjelmeland AB. Kinomic profiling of glioblastoma cells reveals PLCG1 as a target in restricted glucose. Biomarker Research. 6: 22. PMID 29946469 DOI: 10.1186/S40364-018-0136-9  0.422
2018 Libby CJ, Zhang S, Benavides GA, Scott SE, Li Y, Redmann M, Tran AN, Otamias A, Darley-Usmar V, Napierala M, Zhang J, Augelli-Szafran CE, Zhang W, Hjelmeland AB. Identification of Compounds That Decrease Glioblastoma Growth and Glucose Uptake in Vitro. Acs Chemical Biology. PMID 29905460 DOI: 10.1021/Acschembio.8B00251  0.514
2018 Jones RB, Dorsett KA, Hjelmeland AB, Bellis SL. The ST6Gal-I sialyltransferase protects tumor cells against hypoxia by enhancing HIF-1α signaling. The Journal of Biological Chemistry. PMID 29475939 DOI: 10.1074/Jbc.Ra117.001194  0.474
2018 Nhat Tran A, Walker K, Harrison DG, Chen W, Mobley J, Hocevar L, Hackney JR, Sedaka RS, Pollock JS, Goldberg MS, Hambardzumyan D, Cooper SJ, Gillespie Y, Hjelmeland AB. Reactive Species Balance via GTP Cyclohydrolase I Regulates Glioblastoma Growth and Tumor Initiating Cell Maintenance. Neuro-Oncology. PMID 29409010 DOI: 10.1093/Neuonc/Noy012  0.491
2018 Libby CJ, Tran AN, Scott SE, Griguer C, Hjelmeland AB. The Pro-tumorigenic Effects of Metabolic Alterations in Glioblastoma Including Brain Tumor Initiating Cells. Biochimica Et Biophysica Acta. PMID 29378228 DOI: 10.1016/J.Bbcan.2018.01.004  0.472
2018 Jones RB, Dorsett KA, Hjelmeland AB, Bellis SL. Abstract 2435: ST6Gal-I sialylation potentiates hypoxia adaptation by enhancing HIF-1a signaling Cancer Research. 78: 2435-2435. DOI: 10.1158/1538-7445.Am2018-2435  0.482
2018 Tran AN, Walker K, Harrison DG, Chen W, Mobley J, Hocevar L, Hackney JR, Sedaka R, Pollock J, Goldberg MS, Hambardzumyan D, Cooper SJ, Gillespie GY, Hjelmeland AB. Abstract 163: Glioblastoma, cancer stem cells, and reactive species balances: A case for GTP cyclohydrolase 1 Tumor Biology. DOI: 10.1158/1538-7445.Am2018-163  0.391
2018 Eustace N, Warram J, Widden H, Anderson J, Hicks P, Troelsgaard R, Placzek W, Hjelmeland A, Gillespie Y, Willey C. EXTH-52. USE OF A PHOSPHOLIPID BINDING MARCKS MIMETIC FOR TARGETED KILLING OF GLIOBLASTOMA CELLS Neuro-Oncology. 20: vi96-vi96. DOI: 10.1093/Neuonc/Noy148.400  0.334
2018 Scott S, Libby C, Hjelmeland A. DDIS-15. A NOVEL DOPAMINE RECEPTOR 3 ANTAGONIST INHIBITS THE GROWTH OF PRIMARY AND TEMOZOLOMIDE RESISTANT GLIOBLASTOMA CELLS Neuro-Oncology. 20: vi72-vi72. DOI: 10.1093/Neuonc/Noy148.294  0.317
2018 Boyd N, Ayokanmbi A, Walker K, Whetsel J, Gordillo J, Smith C, Gordon E, Herting C, Hambardzumyan D, Gillespie Y, Hackney J, Cooper S, Jiao K, Hjelmeland A. TMIC-08. CHD7 IS SUPPRESSED IN THE PERINECROTIC/ISCHEMIC MICROENVIRONMENT AND IS A NOVEL REGULATOR OF ANGIOGENESIS Neuro-Oncology. 20: vi257-vi257. DOI: 10.1093/Neuonc/Noy148.1068  0.477
2018 Spurlock B, Parker D, Basu M, Hjelmeland A, Mitra K. Modulation of mitochondrial fission activity maintains ovarian tumor initiating cells dependent on mitochondrial energetics Free Radical Biology and Medicine. 128: S74. DOI: 10.1016/J.Freeradbiomed.2018.10.160  0.33
2017 Boyd NH, Walker K, Fried J, Hackney JR, McDonald PC, Benavides GA, Spina R, Audia A, Scott SE, Libby CJ, Tran AN, Bevensee MO, Griguer C, Nozell S, Gillespie GY, ... ... Hjelmeland AB, et al. Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo. Jci Insight. 2. PMID 29263302 DOI: 10.1172/Jci.Insight.92928  0.52
2017 Gilbert AN, Walker K, Tran AN, Boyd NH, Gillespie GY, Singh RK, Hjelmeland AB. Modeling Physiologic Microenvironments in Three-Dimensional Microtumors Maintains Brain Tumor Initiating Cells. Journal of Cancer Stem Cell Research. 5. PMID 29075651 DOI: 10.14343/JCSCR.2017.5e1004  0.455
2017 Rowse AL, Gibson SA, Meares GP, Rajbhandari R, Nozell SE, Dees KJ, Hjelmeland AB, McFarland BC, Benveniste EN. Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells. Journal of Neuro-Oncology. PMID 28181105 DOI: 10.1007/S11060-017-2378-Z  0.481
2017 Tran AN, Walker K, Harisson D, Chen W, Mobley J, Hocevar L, Hackney JR, Sedaka RS, Pollock JS, Cooper SJ, Gillespie GY, Hjelmeland AB. Abstract 5462: GTP cyclohydrolase in brain tumor stem cells is implicated in glioblastoma growth Cancer Research. 77: 5462-5462. DOI: 10.1158/1538-7445.Am2017-5462  0.499
2017 Gilbert A, Walker K, Tran A, Gillespie Y, Singh R, Hjelmeland AB. Abstract 1925: Modeling physiologic microenvironments in three-dimensional microtumors facilitates brain tumor initiating cell maintenance Cancer Research. 77: 1925-1925. DOI: 10.1158/1538-7445.Am2017-1925  0.536
2017 Boyd NH, Walker K, McDonald PC, Bevensee MO, Gillespie YG, Nabors B, Dedhar S, Hjelmeland AB. Abstract 171: Targeting the tumor microenvironment: inhibition of carbonic anhydrase 9 impedes brain tumor initiating cell chemoresistance and delays glioblastoma growth in vivo Cancer Research. 77: 171-171. DOI: 10.1158/1538-7445.Am2017-171  0.469
2017 Tran A, Walker K, Harrison D, Chen W, Mobley J, Hocevar L, Hackney J, Sedaka R, Pollock J, Darley-Usmar V, Cooper S, Gillespie Y, Hjelmeland A. STEM-35. GTP CYCLOHYDROLASE I IN TUMOR INITIATING CELL MAINTENANCE AND GLIOBLASTOMA GROWTH: FUNCTIONS AND MECHANISMS Neuro-Oncology. 19: vi233-vi233. DOI: 10.1093/Neuonc/Nox168.949  0.505
2017 Libby C, Zhang S, Benavides G, Li Y, Redmann M, Tran A, Otamias A, Darley-Usmar V, Napierla M, Zhang J, Zhang W, Hjelmeland A. DDIS-01. INHIBITION OF BRAIN TUMOR INITIATING CELL GROWTH VIA NOVEL GLUCOSE TRANSPORTER ANTAGONISTS Neuro-Oncology. 19: vi59-vi59. DOI: 10.1093/Neuonc/Nox168.237  0.413
2017 Tran AN, Walker K, Harrison D, Chen W, Mobley J, Sedaka R, Pollock J, Darley-Usmar V, Cooper S, Yancey Gillespie G, Hackey JR, Hocevar L, Hjelmeland A. GTP Cyclohydrolase I in Tumor Initiating Cell Maintenance and Glioblastoma Growth: Functions and Mechanisms Free Radical Biology and Medicine. 112: 104. DOI: 10.1016/J.Freeradbiomed.2017.10.157  0.513
2016 Tran AN, Boyd N, Walker K, Hjelmeland A. NOS Expression and NO Function in Glioma and Implications for Patient Therapies. Antioxidants & Redox Signaling. PMID 27411305 DOI: 10.1089/Ars.2016.6820  0.444
2016 Chen CC, Moskwa P, Zinn PO, Hirshman BR, Choi YE, Shukla SA, Fendler W, Lu J, Golub TR, Hjelmeland A, Chowdhury D. 334 A Functional Screen Identifies miRNAs that Induce Radioresistance in Glioblastomas. Neurosurgery. 63: 197-198. PMID 27399532 DOI: 10.1227/01.Neu.0000489823.07757.6E  0.32
2016 Hjelmeland A, Zhang J. Metabolic, autophagic, and mitophagic activities in cancer initiation and progression. Biomedical Journal. 39: 98-106. PMID 27372165 DOI: 10.1016/J.Bj.2015.10.002  0.401
2016 Gilbert A, Walker K, Tran A, Gillespie Y, Singh R, Hjelmeland A. TMOD-18. THREE-DIMENSIONAL MICROTUMORS IN PHYSIOLOGIC MICROENVIRONMENTS MAINTAIN BRAIN TUMOR INITIATING CELLS Neuro-Oncology. 18: vi210-vi210. DOI: 10.1093/Neuonc/Now212.888  0.459
2016 Walker K, Boyd N, McDonald P, Bevensee M, Gillespie Y, Nabors B, Dedhar S, Hjelmeland A. EXTH-26. TARGETING BRAIN TUMOR INITIATING CELL CHEMORESISTANCE WITH THE CARBONIC ANHYDRASE IX INHIBITOR SLC-0111 DELAYS GLIOBLASTOMA GROWTH IN VIVO Neuro-Oncology. 18: vi65-vi65. DOI: 10.1093/Neuonc/Now212.270  0.445
2016 Stafman LL, Hjelmeland A, Mruthyunjayappa S, Garner EF, Atigadda VR, Stewart J, Grubbs CJ, Muccio D, Beierle EA. Novel Retinoid UAB30 Decreases Tumorigenicity and Cancer Stem Cell Maintenance in Human Neuroblastoma Patient-Derived Xenografts Journal of the American College of Surgeons. 223: e160-e161. DOI: 10.1016/J.Jamcollsurg.2016.08.409  0.432
2015 Parker D, Iyer A, Shah S, Moran A, Hjelmeland A, Basu MK, Liu R, Mitra K. A novel mitochondrial pool of Cyclin E, regulated by Drp1, is linked to cell density dependent cell proliferation. Journal of Cell Science. PMID 26446260 DOI: 10.1242/Jcs.172429  0.408
2015 Cheng P, Phillips E, Kim SH, Taylor D, Hielscher T, Puccio L, Hjelmeland AB, Lichter P, Nakano I, Goidts V. Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells. Stem Cell Reports. 4: 899-913. PMID 25921812 DOI: 10.1016/J.Stemcr.2015.03.005  0.5
2015 Rivera M, Wu Q, Hamerlik P, Hjelmeland AB, Bao S, Rich JN. Acquisition of meiotic DNA repair regulators maintain genome stability in glioblastoma. Cell Death & Disease. 6: e1732. PMID 25906155 DOI: 10.1038/Cddis.2015.75  0.461
2015 Stoltz K, Sinyuk M, Hale JS, Wu Q, Otvos B, Walker K, Vasanji A, Rich JN, Hjelmeland AB, Lathia JD. Development of a Sox2 reporter system modeling cellular heterogeneity in glioma. Neuro-Oncology. 17: 361-71. PMID 25416826 DOI: 10.1093/Neuonc/Nou320  0.364
2015 Rivera M, Wu Q, Hamerlik P, Hjelmeland A, Bao S, Rich J. Abstract B44: Acquisition of meiotic DNA repair regulators maintain genome stability in glioblastoma Brain. 75. DOI: 10.1158/1538-7445.Brain15-B44  0.444
2014 Walker K, Hjelmeland A. Method for Efficient Transduction of Cancer Stem Cells. Journal of Cancer Stem Cell Research. 2. PMID 27547779 DOI: 10.14343/JCSCR.2014.2E1008  0.307
2014 Liu JK, Lubelski D, Schonberg DL, Wu Q, Hale JS, Flavahan WA, Mulkearns-Hubert EE, Man J, Hjelmeland AB, Yu J, Lathia JD, Rich JN. Phage display discovery of novel molecular targets in glioblastoma-initiating cells. Cell Death and Differentiation. 21: 1325-39. PMID 24832468 DOI: 10.1038/Cdd.2014.65  0.465
2014 Yan K, Wu Q, Yan DH, Lee CH, Rahim N, Tritschler I, DeVecchio J, Kalady MF, Hjelmeland AB, Rich JN. Glioma cancer stem cells secrete Gremlin1 to promote their maintenance within the tumor hierarchy. Genes & Development. 28: 1085-100. PMID 24788093 DOI: 10.1101/Gad.235515.113  0.56
2014 Scott JG, Hjelmeland AB, Chinnaiyan P, Anderson AR, Basanta D. Microenvironmental variables must influence intrinsic phenotypic parameters of cancer stem cells to affect tumourigenicity. Plos Computational Biology. 10: e1003433. PMID 24453958 DOI: 10.1371/Journal.Pcbi.1003433  0.426
2014 Lathia JD, Li M, Sinyuk M, Alvarado AG, Flavahan WA, Stoltz K, Rosager AM, Hale J, Hitomi M, Gallagher J, Wu Q, Martin J, Vidal JG, Nakano I, Dahlrot RH, ... ... Hjelmeland AB, et al. High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor. Cell Reports. 6: 117-29. PMID 24373972 DOI: 10.1016/J.Celrep.2013.11.043  0.496
2014 Venere M, Hamerlik P, Wu Q, Rasmussen RD, Song LA, Vasanji A, Tenley N, Flavahan WA, Hjelmeland AB, Bartek J, Rich JN. Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells. Cell Death and Differentiation. 21: 258-69. PMID 24121277 DOI: 10.1038/Cdd.2013.136  0.411
2014 Rowse A, McFarland B, Meares G, Zheng Y, Hjelmeland A, Benveniste E. Cs-30Protein Kinase Ck2 Is Important For The Function Of Glioblastoma Brain Tumor Initiating Cells Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou242.30  0.489
2013 Lotti F, Jarrar AM, Pai RK, Hitomi M, Lathia J, Mace A, Gantt GA, Sukhdeo K, DeVecchio J, Vasanji A, Leahy P, Hjelmeland AB, Kalady MF, Rich JN. Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. The Journal of Experimental Medicine. 210: 2851-72. PMID 24323355 DOI: 10.1084/Jem.20131195  0.415
2013 Flavahan WA, Wu Q, Hitomi M, Rahim N, Kim Y, Sloan AE, Weil RJ, Nakano I, Sarkaria JN, Stringer BW, Day BW, Li M, Lathia JD, Rich JN, Hjelmeland AB. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nature Neuroscience. 16: 1373-82. PMID 23995067 DOI: 10.1038/Nn.3510  0.458
2013 Kim Y, Wu Q, Hamerlik P, Hitomi M, Sloan AE, Barnett GH, Weil RJ, Leahy P, Hjelmeland AB, Rich JN. Aptamer identification of brain tumor-initiating cells. Cancer Research. 73: 4923-36. PMID 23796560 DOI: 10.1158/0008-5472.Can-12-4556  0.525
2013 Sukhdeo K, Paramban RI, Vidal JG, Elia J, Martin J, Rivera M, Carrasco DR, Jarrar A, Kalady MF, Carson CT, Balderas R, Hjelmeland AB, Lathia JD, Rich JN. Multiplex flow cytometry barcoding and antibody arrays identify surface antigen profiles of primary and metastatic colon cancer cell lines. Plos One. 8: e53015. PMID 23308131 DOI: 10.1371/Journal.Pone.0053015  0.409
2012 Lathia JD, Li M, Hall PE, Gallagher J, Hale JS, Wu Q, Venere M, Levy E, Rani MR, Huang P, Bae E, Selfridge J, Cheng L, Guvenc H, McLendon RE, ... ... Hjelmeland AB, et al. Laminin alpha 2 enables glioblastoma stem cell growth. Annals of Neurology. 72: 766-78. PMID 23280793 DOI: 10.1002/Ana.23674  0.56
2012 Hjelmeland AB, Rich JN. The quest for self-identity: not all cancer stem cells are the same. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3495-8. PMID 22711710 DOI: 10.1158/1078-0432.Ccr-12-1456  0.447
2012 Kim Y, Kim E, Wu Q, Guryanova O, Hitomi M, Lathia JD, Serwanski D, Sloan AE, Weil RJ, Lee J, Nishiyama A, Bao S, Hjelmeland AB, Rich JN. Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. Genes & Development. 26: 1247-62. PMID 22661233 DOI: 10.1101/Gad.193565.112  0.509
2012 Heddleston JM, Wu Q, Rivera M, Minhas S, Lathia JD, Sloan AE, Iliopoulos O, Hjelmeland AB, Rich JN. Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. Cell Death and Differentiation. 19: 428-39. PMID 21836617 DOI: 10.1038/Cdd.2011.109  0.532
2012 Kim Y, Kim E, Guryanova O, Hitomi M, Sloan AE, Hjelmeland AB, Rich JN. Abstract 5192: Platelet derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity Cancer Research. 72: 5192-5192. DOI: 10.1158/1538-7445.Am2012-5192  0.53
2012 Rivera M, Hjelmeland A, Rich J. Abstract 3370: DNA repair in glioma stem cell-mediated radiation resistance Cancer Research. 72: 3370-3370. DOI: 10.1158/1538-7445.Am2012-3370  0.357
2012 Kozono D, Nitta M, Sampetrean O, Kimberly N, Kushwaha D, Merzon D, Ligon K, Zhu S, Zhu K, Kim TH, Kwon C, Becher O, Saya H, Chen CC, Donovan LK, ... ... Hjelmeland A, ... ... Hjelmeland A, ... ... Hjelmeland AB, ... ... Hjelmeland AB, ... ... Hjelmeland AB, ... ... Hjelmeland A, ... ... Hjelmeland A, et al. LAB-STEM CELLS Neuro-Oncology. 14: vi142-vi152. DOI: 10.1093/Neuonc/Nos239  0.424
2011 Hjelmeland AB, Lathia JD, Sathornsumetee S, Rich JN. Twisted tango: brain tumor neurovascular interactions. Nature Neuroscience. 14: 1375-81. PMID 22030548 DOI: 10.1038/Nn.2955  0.522
2011 Lathia JD, Gallagher J, Myers JT, Li M, Vasanji A, McLendon RE, Hjelmeland AB, Huang AY, Rich JN. Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. Plos One. 6: e24807. PMID 21961046 DOI: 10.1371/Journal.Pone.0024807  0.527
2011 Lathia JD, Hitomi M, Gallagher J, Gadani SP, Adkins J, Vasanji A, Liu L, Eyler CE, Heddleston JM, Wu Q, Minhas S, Soeda A, Hoeppner DJ, Ravin R, McKay RD, ... ... Hjelmeland AB, et al. Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell Death & Disease. 2: e200. PMID 21881602 DOI: 10.1038/Cddis.2011.80  0.479
2011 Heddleston JM, Hitomi M, Venere M, Flavahan WA, Yang K, Kim Y, Minhas S, Rich JN, Hjelmeland AB. Glioma stem cell maintenance: the role of the microenvironment. Current Pharmaceutical Design. 17: 2386-401. PMID 21827414 DOI: 10.2174/138161211797249260  0.516
2011 Eyler CE, Wu Q, Yan K, MacSwords JM, Chandler-Militello D, Misuraca KL, Lathia JD, Forrester MT, Lee J, Stamler JS, Goldman SA, Bredel M, McLendon RE, Sloan AE, Hjelmeland AB, et al. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell. 146: 53-66. PMID 21729780 DOI: 10.1016/J.Cell.2011.06.006  0.556
2011 Guryanova OA, Wu Q, Cheng L, Lathia JD, Huang Z, Yang J, MacSwords J, Eyler CE, McLendon RE, Heddleston JM, Shou W, Hambardzumyan D, Lee J, Hjelmeland AB, Sloan AE, et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell. 19: 498-511. PMID 21481791 DOI: 10.1016/J.Ccr.2011.03.004  0.495
2011 Hjelmeland AB, Rich JN. Molecular targeting of neural cancer stem cells: TTAGGG, you're it! Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3-5. PMID 21208901 DOI: 10.1158/1078-0432.Ccr-10-2686  0.496
2011 Hjelmeland AB, Wu Q, Heddleston JM, Choudhary GS, MacSwords J, Lathia JD, McLendon R, Lindner D, Sloan A, Rich JN. Acidic stress promotes a glioma stem cell phenotype. Cell Death and Differentiation. 18: 829-40. PMID 21127501 DOI: 10.1038/Cdd.2010.150  0.531
2011 Wang H, Wang X, Rich J, Wang Q, Hjelmeland A. Abstract 3311: IL6-Stat3 signaling promotes glioma stem cell (GSC) survival under hypoxia environment through inhibition of cell-death inducing gene Bnip3 Cancer Research. 71: 3311-3311. DOI: 10.1158/1538-7445.Am2011-3311  0.481
2010 Cao Y, Lathia JD, Eyler CE, Wu Q, Li Z, Wang H, McLendon RE, Hjelmeland AB, Rich JN. Erythropoietin Receptor Signaling Through STAT3 Is Required For Glioma Stem Cell Maintenance. Genes & Cancer. 1: 50-61. PMID 20657792 DOI: 10.1177/1947601909356352  0.565
2010 Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, Macswords J, Wu Q, Vasanji A, McLendon RE, Hjelmeland AB, Rich JN. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell. 6: 421-32. PMID 20452317 DOI: 10.1016/J.Stem.2010.02.018  0.496
2010 Hjelmeland AB, Wu Q, Wickman S, Eyler C, Heddleston J, Shi Q, Lathia JD, Macswords J, Lee J, McLendon RE, Rich JN. Targeting A20 decreases glioma stem cell survival and tumor growth. Plos Biology. 8: e1000319. PMID 20186265 DOI: 10.1371/Journal.Pbio.1000319  0.436
2010 Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, Rich JN. Hypoxia inducible factors in cancer stem cells. British Journal of Cancer. 102: 789-95. PMID 20104230 DOI: 10.1038/Sj.Bjc.6605551  0.458
2010 Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, Rich JN, Sullenger BA. Notch promotes radioresistance of glioma stem cells. Stem Cells (Dayton, Ohio). 28: 17-28. PMID 19921751 DOI: 10.1002/Stem.261  0.509
2010 Eyler CE, Forrester MT, MacSwords JM, Wu Q, LaFiura KM, Lathia JD, Sloan AE, Lee J, McLendon RE, Hjelmeland AB, Rich JN. Abstract 3318: Molecular targeting of brain tumor stem cells Cancer Research. 70: 3318-3318. DOI: 10.1158/1538-7445.Am10-3318  0.567
2009 Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle (Georgetown, Tex.). 8: 3274-84. PMID 19770585 DOI: 10.4161/Cc.8.20.9701  0.508
2009 Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM, Eyler CE, Elderbroom J, Gallagher J, Schuschu J, MacSwords J, Cao Y, McLendon RE, Wang XF, Hjelmeland AB, et al. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells (Dayton, Ohio). 27: 2393-404. PMID 19658188 DOI: 10.1002/Stem.188  0.399
2009 Schilling SH, Hjelmeland AB, Radiloff DR, Liu IM, Wakeman TP, Fielhauer JR, Foster EH, Lathia JD, Rich JN, Wang XF, Datto MB. NDRG4 is required for cell cycle progression and survival in glioblastoma cells. The Journal of Biological Chemistry. 284: 25160-9. PMID 19592488 DOI: 10.1074/Jbc.M109.012484  0.714
2009 Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, Hjelmeland AB, Rich JN. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 15: 501-13. PMID 19477429 DOI: 10.1016/J.Ccr.2009.03.018  0.595
2009 Li Z, Wang H, Eyler CE, Hjelmeland AB, Rich JN. Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways. The Journal of Biological Chemistry. 284: 16705-9. PMID 19286664 DOI: 10.1074/Jbc.R900013200  0.592
2008 Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE, Hjelmeland AB, Rich JN. c-Myc is required for maintenance of glioma cancer stem cells. Plos One. 3: e3769. PMID 19020659 DOI: 10.1371/Journal.Pone.0003769  0.571
2008 Eyler CE, Foo WC, LaFiura KM, McLendon RE, Hjelmeland AB, Rich JN. Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells (Dayton, Ohio). 26: 3027-36. PMID 18802038 DOI: 10.1634/Stemcells.2007-1073  0.557
2008 Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, Hjelmeland AB, Rich JN. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Research. 68: 6043-8. PMID 18676824 DOI: 10.1158/0008-5472.Can-08-1079  0.623
2007 Hjelmeland AB, Lattimore KP, Fee BE, Shi Q, Wickman S, Keir ST, Hjelmeland MD, Batt D, Bigner DD, Friedman HS, Rich JN. The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. Molecular Cancer Therapeutics. 6: 2449-57. PMID 17766837 DOI: 10.1158/1535-7163.Mct-07-0155  0.454
2007 Shi Q, Hjelmeland AB, Keir ST, Song L, Wickman S, Jackson D, Ohmori O, Bigner DD, Friedman HS, Rich JN. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Molecular Carcinogenesis. 46: 488-96. PMID 17219439 DOI: 10.1002/Mc.20297  0.438
2007 Shi Q, Bao S, Song L, Wu Q, Bigner DD, Hjelmeland AB, Rich JN. Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene. 26: 4084-94. PMID 17213807 DOI: 10.1038/Sj.Onc.1210181  0.459
2006 Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444: 756-60. PMID 17051156 DOI: 10.1038/Nature05236  0.46
2006 Sathornsumetee S, Hjelmeland AB, Keir ST, McLendon RE, Batt D, Ramsey T, Yusuff N, Rasheed BK, Kieran MW, Laforme A, Bigner DD, Friedman HS, Rich JN. AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. Cancer Research. 66: 8722-30. PMID 16951188 DOI: 10.1158/0008-5472.Can-06-0284  0.473
2006 Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Research. 66: 7843-8. PMID 16912155 DOI: 10.1158/0008-5472.Can-06-1010  0.538
2006 Rich JN, Shi Q, Hjelmeland AB, Keir ST, Wickman S, Wu G, Jackson D, Ohmori O, Bigner DD, Friedman HS. A novel low molecular weight inhibitor of focal adhesion kinase and insulin-like growth factor-1 receptor, TAE226, inhibits glioma growth Journal of Clinical Oncology. 24: 11505-11505. DOI: 10.1200/Jco.2006.24.18_Suppl.11505  0.425
2005 Hjelmeland AB, Hjelmeland MD, Shi Q, Hart JL, Bigner DD, Wang XF, Kontos CD, Rich JN. Loss of phosphatase and tensin homologue increases transforming growth factor beta-mediated invasion with enhanced SMAD3 transcriptional activity. Cancer Research. 65: 11276-81. PMID 16357132 DOI: 10.1158/0008-5472.Can-05-3016  0.34
2005 Hjelmeland AB, Schilling SH, Guo X, Quarles D, Wang XF. Loss of Smad3-mediated negative regulation of Runx2 activity leads to an alteration in cell fate determination. Molecular and Cellular Biology. 25: 9460-8. PMID 16227596 DOI: 10.1128/Mcb.25.21.9460-9468.2005  0.658
Show low-probability matches.